Prascend
Is the registration number of your country not listed? Then this product falls within the cascade control system.
Prascend
Composition:
Prascend Tablets. Each Prascend tablet contains 1.0 mg pergolide (as pergolide mesylate 1.31 mg).
Indications:
Symptomatic treatment of clinical signs associated with Pituitary Pars Intermedia Dysfunction (PPID) (Equine Cushing’s Disease).
Contra-indications:
Do not use in horses with known hypersensitivity to pergolide mesylate or other ergot derivatives.
Do not use in horses less than 2 years of age.
Do not use in horses intended for human consumption.
Side-effects:
Potential adverse reactions in horses include sweating, inappetence, transient anorexia and lethargy, mild central nervous system signs (e.g. mild depression and mild ataxia), diarrhoea and colic. If signs of dose intolerance develop, treatment should be stopped for 2 to 3 days and reinstated at one-half of the previous dose. The total daily dose may then be titrated back up to the desired clinical effect by 0.5 mg increments every 2 to 4 weeks.
Dosage and administration:
The product should be administered orally, once daily.
The starting dose is 2 µg/kg. The recommended doses are as follows:
200 - 400 kg of body weight: 1/2 tablet
401 - 600 kg of body weight: 1 tablet
601 - 850 kg of body weight: 1 1/2 tablets
851 - 1000 kg of body weight: 2 tablets
1.0 mg pergolide/ tablet (as pergolide mesylate 1.31 mg)
| Nr. | BOE006 |
|---|---|
| Registration number | NL: REG NL 110598 |
| Brand | Boehringer Ingelheim |
| Chilled item | No |
| Active Ingredient | Pergolide |
| Target species | Horse |
| Legal status of supply | UDA |
| Route of administration | Oral |
| Units per outer box | 0 |
| Ingredients | 1.0 mg pergolide/ tablet (as pergolide mesylate 1.31 mg) |